048410.KQ
Hyundai Bioscience Co., Ltd.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 6,050.00
−0.49%Year over year
Reported trailing growth
- Revenue
- +78.0%
- EBITDA
- -72.7%
- EBIT
- -26.6%
- EPS
- -16.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -23.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026